The exchange is wrapping up next week so I suspect
Post# of 30066
(Total Views: 471)
Posted On: 03/10/2018 11:08:25 AM
Re: All Aboard #26218
The exchange is wrapping up next week so I suspect we'll hear about it 2-3 days later. IF the company has potential investors lined up for Elto, ESS and/or MANF, then it's off to the raises.
The Sachs BioCapital USA Forum is timed perfectly on March 21. GC is on a panel just before Noon and has a 20 minute investors presentation in the afternoon.
https://www.dropbox.com/s/sayd9lxekbdqda3/BCU...2.pdf?dl=0
This will now be the 3rd conference this year. Note that none of this was geared towards retail as we haven't seen a presentation or replay.
The Sachs BioCapital USA Forum is timed perfectly on March 21. GC is on a panel just before Noon and has a 20 minute investors presentation in the afternoon.
https://www.dropbox.com/s/sayd9lxekbdqda3/BCU...2.pdf?dl=0
This will now be the 3rd conference this year. Note that none of this was geared towards retail as we haven't seen a presentation or replay.
Quote:
Amarantus will be participating in Redefining Early Stage Investments (RESI) JPM 2018 on Tuesday January 9, 2018 at the Marines' Memorial Club & Hotel in San Francisco, CA.
Quote:
Concurrent with this announcement, the Company's CEO will be presenting an overview of Elto Pharma's pending Phase 2b Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and Cutanogen Corporation's pending pivotal trial in Pediatric Severe Burns on Thursday March 1st, 2018 at 9:45pa ET at the BIOCOM Global Life Science Partnering Conference in San Diego, CA.
Quote:
Elto Pharma, Inc., an orphan specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), that is advancing Eltoprazine into a Phase 2b clinical trial for the treatment of the orphan indication Parkinson's disease levodopa-induced dyskinesia (PD-LID), today announced that it will be presenting a summary of its pending Phase 2b PD-LID clinical program and participating in the neuroscience panel at the Sachs BioCapital USA Forum on March 21, 2018 at the New York Academy of Sciences (NYAS) in New York City. The neuroscience panel is entitled "Renewed Approaches for Neuroscience."
Quote:
The exchange period is expected to be completed on or before March 17, 2018. Holders of 96% of securities eligible for the Tender Exchange have executed the LOIs acknowledging their participation in the Company's recapitalization effort. Holders of the remaining 4% of securities eligible for the Tender Exchange are able to participate until the expiration of the exchange period.
Upon completion of the Tender Exchange, the Company intends to utilize funding mechanisms created under the JOBS Act to raise equity capital. The Company intends for its subsidiaries to raise capital independently to advance their business plans , thereby limiting Amarantus' ongoing need to fund the subsidiaries' product development programs, and limiting future dilution.
(6)
(0)